Armodafinil
From Wikipedia, the free encyclopedia
| Image:Armodafinil.png | |
| Armodafinil
| |
| Systematic (IUPAC) name | |
| (r)-2-((diphenylmethyl)sulfinyl)-acetamide | |
| Identifiers | |
| CAS number | 68693-11-8 |
| ATC code | N06BA07 |
| PubChem | ? |
| Chemical data | |
| Formula | C15H15NO2S |
| Mol. weight | 273.351 |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | Hepatic, including CYP3A4 and other pathways |
| Half life | 12-15 hrs |
| Excretion | Urine (as metabolites) |
| Therapeutic considerations | |
| Pregnancy cat. |
C |
| Legal status |
Schedule IV (USA) |
| Routes | Oral |
Armodafinil (Nuvigil®) is an eugeroic drug produced by the pharmaceutical company Cephalon Inc., currently in the process of receiving Food and Drug Administration (FDA) approval. Armodafinil is the r-enantiomer of modafinil, so is expected to act in a similar manner, with similar effects. However, it acts for a longer duration of time than modafinil. Upon approval, it is expected to be classified as a Schedule IV controlled substance.
[edit] See also
[edit] External links

